Personal cancer vaccine cuts melanoma return risk by 42%
A vaccine made from a patient’s own tumour has cut the risk of melanoma returning by 42% in a large international trial. Researchers are calling it a landmark moment in cancer treatment. The phase 3 trial, called INTerpath-001, involved 1,137 patients whose melanoma had been removed by surgery but who were at very high risk … Read more
